ALGN changes
Pick any two versions below to diff them.
- Price
- $149.89 → $172.08(+14.8%)
- Discount category
- Below intrinsic value → Close to intrinsic value
- Balance sheet
- Cash: $1.1B Debt: $0.0M Net cash: $1.1B Undrawn credit line: $300M, to December 2027 Align has no debt and funds its operations with cash from operations. At September 30, 2026, cash and cash equivalents were $1,144.9 million, up from $1,102.6 million at June 30, 2026. Its $300 million unsecured revolving credit facility matures on December 23, 2027, and the full $300 million was available at September 30, 2026. In Q3 2026, Align bought back about 627,300 shares at an average price of $164.73, and $630.0 million remained under its $1.0 billion repurchase program at September 30, 2026. Align expects to buy back up to $300 million of shares in Q4 2026 and about $500 million in all of 2026. added: On November 5, 2026, it agreed an accelerated share repurchase of $270 million, paid in advance, and $600 million then remained available under the program. It expects 2026 capital expenditures of $125 million to $150 million. Interest cover is not shown, because Align has no debt. As of Sep 30, 2026.
- Recent events
- added: Nov 5, 2026: Align agreed an accelerated share repurchase with Goldman Sachs for $270 million of its common stock. It paid $270 million at once and received about 1.44 million shares at the start. The final number of shares depends on the average share price during the period, and settlement is due by about December 29, 2026. After this agreement, $600 million remained available under the April 2025 buyback program. Oct 28, 2026: Align reported Q3 2026 results. Revenues rose 1.9% to $1,014.8 million, within the outlook of $1,000 million to $1,020 million. Clear Aligner volume rose 6.6% to 690.6 thousand cases, and Imaging Systems and CAD/CAM Services revenues fell 7.6%. GAAP EPS was $1.90 and non-GAAP EPS was $2.80. The non-GAAP operating margin was 24.4%. Align expects 2026 revenues of $4,110 million to $4,130 million, a non-GAAP operating margin of about 23.7% and about $500 million of share buybacks. It started a restructuring plan in Q3 2026 to reduce headcount and costs. Oct 28, 2026: Align said that the board appointed Jennifer L. Davis as CEO-elect and director from November 2, 2026, and as President and CEO from December 31, 2026. She was CEO of Procter & Gamble's health care business until June 2026. Joseph M. Hogan, CEO since 2015, retires as CEO on December 31, 2026, becomes a strategic advisor and stays on the board until June 2027. Aug 27, 2026: The board appointed Quentin Blackford as a director and increased the board to eleven members. Jul 29, 2026: Align reported Q2 2026 results. Revenues rose 4.3% to a record $1.06 billion, and Clear Aligner volume rose 7.4% to a record 691.8 thousand cases. Imaging Systems and CAD/CAM Services revenues fell 10.8%. GAAP EPS was $1.51, after a $38 million UK VAT liability, and non-GAAP EPS was $2.64. Align expected Q3 2026 revenues of $1,000 million to $1,020 million and kept its 2026 revenue growth outlook of 3% to 4%. Jul 29, 2026: After talks with Elliott Investment Management, Align said that it will add three new independent directors and review its strategy and operating model with a global consulting firm. It raised its 2026 share repurchase plan to $400 million to $500 million. Jul 6, 2026: Julie Coletti, Chief Legal and Regulatory Officer, resigned to join Illumina as Chief Legal Officer, effective August 1, 2026. Jun 30, 2026: The European Commission opened a formal antitrust investigation into Align. It examines whether Align abused a dominant position for Invisalign aligners, because Invisalign did not accept orders and scans from competing intraoral scanners. Align said that it will cooperate and that the opening of the investigation is a procedural step. Jun 17, 2026: C. Raymond Larkin, Jr. said that he will retire as Chairman on July 1, 2026, and leave the board on December 31, 2026. The board named Kevin Conroy, an independent director, as Chairman from July 1, 2026.